Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

SRL Diagnostics Partners with PathPresenter to Enable Digital Pathology Consultations

PathPresenter

SRL Diagnostics, India’s largest diagnostics services network, today announced that it has partnered with PathPresenter, the global image sharing platform for pathology, to enable digital pathology consultations between SRL’s state of the art reference laboratories in Mumbai, Gurugram, and Bengaluru. SRL has been at the forefront of introducing and adopting the latest in advanced laboratory technologies. With robust IT infrastructure and information management system, SRL Diagnostics is all set to pioneer digital pathology and its large scale adoption in India. SRL Diagnostics will deploy PathPresenter’s clinical consultation platform to empower specialist pathologists at the company’s reference laboratories to quickly and easily sign-out pathology cases uploaded from remote locations in SRL’s laboratory network. This new capability represents a significant shift from a microscope-based standard of care to the use of digital whole slide images, which will help lay the foundation for SRL pathologists to deliver second opinion services that can better inform patient treatment decisions and sets a new benchmark of use of the technology of digital pathology in India. Announcing the partnership, Mr. Anand K, Chief Executive Officer of SRL Diagnostics said “Digital Pathology circumvents the need to travel to a workplace to report cases; thereby ensuring that clinicians and patients get accurate diagnostic insights wherever they are. Through this partnership, we are proud and excited to pioneer this on a large scale in India and raise the bar of diagnostic excellence. In addition to enabling multi-site collaborations, the PathPresenter platform will also aid in disease research involving pathology informatics that requires the archival, retrieval, organization and seamless sharing and analyzing of data sets created by anatomic pathologists. With widespread adoption, digital pathology will also help us reduce our carbon footprint by reducing the logistical requirements of transporting samples for consultation and review.” Dr. Rajendra Singh, Founder of PathPresenter, added “We are thrilled to collaborate with India’s leading diagnostic pathology service provider and create the infrastructure for patients to get a faster report from the most skilled pathologists in the country. This partnership is in line with our mission to help democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical and secure platform to access and use best-in-class AI models.” Dr. Kunal Sharma, Associate Director, CoE, Histopathology said “This collaboration will add impetus to our rapidly expanding digital pathology network. The digitized slides, which are high definition images of glass slides developed from processed tissue blocks, are instantly accessible to pathologists across the globe. This not only mitigates delays due to physical transportation of blocks but also prevents tissue exhaustion due to repeat slide preparation, especially in cases for review/expert opinion. With the PathPresenter platform, we get a seamless and secure access to our digitized cases enabling structured reports integrated with our Lab Information System. It also facilitates development of algorithms using Artificial Intelligence tools, alleviating the subjectivity in reporting.” Given the technology and data revolution in the Indian healthcare system, it will not be long before Digital Pathology becomes a standard of care in laboratory setting where data and artificial intelligence algorithms will transform patient diagnosis and therapeutic management. About SRL Diagnostics Instituted in 1995, SRL Diagnostics is India’s leading diagnostics services provider with presence across 600+ Cities, 30 States and Union Territories. The company has the largest number of NABL and CAP accredited labs in the country with 3 centres of excellence providing high-end histopathology, hematology and molecular diagnostics, serving close to 20 million customers and conducting more than 40 million tests annually via an extensive network of 400+ labs including a Global Reference Laboratory in Mumbai and 5 Regional Reference Laboratories at Gurugram, Chennai, Bengaluru, Kolkata and Kochi. SRL operates over 3000 customer touch points across the country and caters to international markets like South Asia, Africa, Dubai and other parts of Middle East. About PathPresenter PathPresenter is the image sharing platform for pathology, on a mission to democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology pioneer, Dr. Rajendra Singh, PathPresenter has been adopted by 35+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 45,000+ users in 172 countries to easily view and share digital pathology images and knowledge. For more information visit www.pathpresenter.com. Contact Details SRL Diagnostics Nadhiya Mali Head, PR, Brand and Communications 8879009517 / nadhiya.mali@srl.in PathPresenter Cory Batenchuk - SVP of Operations +1 873-355-9913 cory@pathpresenter.com About PathPresenter PathPresenter is the image sharing platform for pathology, on a mission to democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology pioneer, Dr. Rajendra Singh, PathPresenter has been adopted by 35+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 45,000+ users in 172 countries to easily view and share digital pathology images and knowledge. For more information visit www.pathpresenter.com. Contact Details PathPresenter Cory Batenchuk +1 873-355-9913 cory@pathpresenter.com Company Website https://www.pathpresenter.com/

March 08, 2023 09:00 AM Eastern Standard Time

Image

New Study Confirms PayMedix Significantly Increases Net Cash Yield from Commercial Revenue for Hospitals and Healthcare Providers

HPS|PayMedix

MILWAUKEE, March 8, 2023 – At a time when 41% of U.S. adults have some form of healthcare debt, Health Payment Systems, Inc. (HPS) |PayMedix announced its PayMedix healthcare financing solution increases cash yield for healthcare organizations by as much as 9.5%, based on analysis reviewed by the Validation Institute. The savings encompass a healthcare organization’s total commercial allowed revenue, including both insurance and consumer out-of-pocket balances due. Providers do not re-negotiate pay or contracts or re-tool their existing revenue cycle processes. Instead, providers simply agree to participate with PayMedix and receive guaranteed payment. For a hospital with $200 million in commercial revenue, the PayMedix savings would yield $16 million in additional annual cash. Validation Institute is an independent, third-party organization dedicated to improving the quality and cost of healthcare. The review affirms that PayMedix’s ROI calculator produces a reasonable estimate of a healthcare provider’s savings using the PayMedix platform for commercially insured payments. By guaranteeing prompt full payment to healthcare providers and offering patients manageable repayment plans for all allowed in-network costs, regardless of their ability to pay, PayMedix reduces bad debt and increases net cash yield for providers. It eliminates financial risk for providers, as PayMedix assumes full responsibility for collecting patient balances. “Validation Institute’s review confirms the financial impact of PayMedix’s ability to reinvent and simplify the way healthcare payments are made,” said Tom Policelli, CEO of PayMedix. “Soaring out-of-pocket costs have become a $491 billion problem for the healthcare industry, with providers spending more to collect less. Providers no longer need to chase consumers after services are provided or demand payment before delivering care. By paying providers in full, we drastically reduce bad debt and collection costs. This allows providers to focus on what really matters—providing quality care to all patients.” In addition to increasing net cash yield, the PayMedix solution also increases patient access to needed healthcare services. Some patients today delay or avoid care due to cost concerns, and that can negatively impact overall healthcare outcomes and costs. PayMedix fixes that problem and thus increases health equity by guaranteeing payment to all providers for all participating consumers – regardless of their individual credit ratings. Measuring the additional revenue and cash that could be generated by this increase in patient access to services was outside the scope of the Validation Institute study. Any such gains would increase the value of PayMedix to health systems and provider organizations. The Validation Institute review simply certifies that the hard-dollar savings shown in the PayMedix ROI calculator reasonably estimate the savings to providers. PayMedix stands behind these estimates by making full, non-recourse payments to providers based on the model. Validation Institute’s review of PayMedix’s ROI calculator is also backed by the organization’s Credibility Guarantee. Validation Institute offers customers of the PayMedix solution up to $10,000 guarantee for its claims-based validation. This guarantee confirms that PayMedix will achieve what the validation language says it will achieve. “PayMedix is solving a critical financial challenge for healthcare providers by increasing their net cash yield and reducing their bad debt,” said Benny DiCecca, CEO of the Validation Institute. “We congratulate PayMedix for its pioneering work in changing the way people access, use, and pay for healthcare.” About Validation Institute Validation Institute is an independent, objective, third party organization on a mission to improve the quality and cost of healthcare. Based in Woburn, MA the organization is made up of a network of health benefits purchasers, health benefits advisors, and healthcare solution providers focused on delivering better health value and stronger outcomes than conventional healthcare. www.validationinstitute.com About PayMedix PayMedix, which began as the financing arm of Wisconsin-based HPS over a decade ago, is the only company solving the problem of high out-of-pocket costs for everyone: providers, patients, employers and TPAs. By guaranteeing payments to providers and credit for all patients, PayMedix is changing the way people access, use, and pay for healthcare. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. About HPS Health Payment Systems (HPS) is a privately held healthcare technology and services organization with solutions that reduce the cost and complexity of the healthcare payments process to benefit providers, employers, patients and TPAs. Headquartered in Milwaukee, Wisconsin, HPS has an independent network of 96 hospital facilities and 27,000 individual providers. Contact Details Brodeur Partners Kaitlynn Cooney +1 609-351-5944 kcooney@brodeur.com Company Website https://paymedix.com

March 08, 2023 09:00 AM Eastern Standard Time

Roquefort Therapeutics establishes scientific advisory board

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Proactive's Thomas Warner after announcing the creation of a scientific advisory board. Reginald explains the rationale for the decision, before going to explain what each of the three-strong team will bring to Roquefort as it heads toward what he calls “key pre-clinical milestones”. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 08, 2023 08:22 AM Eastern Standard Time

Video

Destiny Pharma "making real progress"

Destiny Pharma PLC

Destiny Pharma PLC (AIM:DEST) chief executive Neil Clark updates Proactive's Thomas Warner on the latest news from the clinical-stage biotech company. The update follows the announcement that Destiny has reached a collaboration and co-development agreement for its phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence. Clark says Destiny Pharma is "making real progess" and delivering on its strategy. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 08, 2023 08:19 AM Eastern Standard Time

Video

Fine Hygienic Holding continues to roll out a progressive female-friendly approach with its latest Menopause and Fertility Treatment Policy

Fine Hygienic Holding

Fine Hygienic Holding (FHH), a world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has recently recommitted to its ongoing mission to make the workplace environment more inclusive and inviting for all its employees. The company has rolled out additional reforms in terms of its female-friendly policies to ensure everyone operates in a supportive environment. A step towards establishing positive change has been made, as the company is introducing the Fine Flourish Policy, which includes provisions for Menstrual, Menopause, and Fertility Treatment leaves, across all its locations. All female personnel - both full-time and probationary - are eligible to take advantage of the generous Fine Flourish policy. Employees are granted up to 12 days of leave annually in the event of any illness, symptoms, or complications related to menopause, menstruation, or fertility treatment. Moreover, flexible work arrangements can be made to ensure their comfort and convenience. All these provisions can be availed without a medical certificate and are granted separately from vacations or other leave policies. FHH is regarded as a pioneer in the region with its employee-friendly leave policies that offer time to recover both physically and emotionally. Kirsty Koen, FHH CHRO, said, “At Fine Hygienic Holding, we believe that a successful business must always prioritize its people. That’s why one of our core values has always been - if we take care of our people, the business will take care of itself. We are constantly exploring new methods and practices that will help ensure our employees are supported in every aspect, especially during times when they need it the most. Every policy we announce is tailored to embody our values and to provide support, and we will continue to be dedicated to looking after the wellbeing of our people and pave the way for woman employment across the Middle East.” Fine Hygienic Holding has already set the bar high in this field when it previously introduced a series of progressive leaves on top of which is its menstrual leave, which the company launched more than 10 years ago. For mothers to be, FHH provides up to 16 weeks of fully paid maternity leave, which is far more than the recommendations of the International Labour Organization. Furthermore, the company has amended its parental leave policy, allowing three weeks of paid paternity leave, and has also set a benchmark in global and regional companies by introducing a compassionate leave wherein a female employee or the spouse of an employee is granted a paid leave in cases of miscarriages or stillbirths. Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director +971 54 531 5575 Rkawalit@finehh.com Company Website https://www.finehh.com/

March 08, 2023 01:40 AM Eastern Standard Time

News Release

1606 Corp lands key acquisition with 51% stake in CBD supplier Brio Nutrition

1606 Corp.

1606 Corp CEO Greg Lambrecht joins Proactive's Natalie Stoberman with details of the company's purchase of a 51% stake in CBD supplier Brio Nutrition. Lambrecht said the acquisition includes the addition of over 45 products to the 1606 lineup, access to all Brio customer data and distribution channels for cross-marketing the 1606 line of products, as well as the opportunity to use 1606 to expand Brio's CBD development and distribution. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

March 07, 2023 01:02 PM Eastern Standard Time

Video

News Release

Mindset Pharma and PharmAla partnership makes first medical grade psilocybin sale in Australia

Mindset Pharma Inc

Mindset Pharma CEO James Lanthier and PharmAla CEO Nick Kadysh join Proactive's Natalie Stoberman to announce their first sale of pharmaceutical grade psilocybin into the Australian market. Lanthier and Kadysh said the psilocybin is being purchased by Reset Mind Sciences Limited, a Western Australian based company focused on psychedelic medicines, and a subsidiary of ASX-listed Little Green Pharma. The CEOs added that regulatory developments in Australia have opened the door to more opportunities for their partnership that combines Mindset's novel synthesis processes and PharmAla's sales infrastructure. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

March 07, 2023 12:06 PM Eastern Standard Time

Video

This ‘Mini-Berkshire Hathaway’ Style Company’s Strategy Of Building And Spinning Off Companies Is Giving Retail Investors Pure-Play Opportunities For Additional Stock

DSS, Inc.

By Ernest Dela Aglanu, Benzinga A company with an investment style seemingly similar to the legendary Berkshire Hathaway Inc. (NYSE: BRK.A) is reporting significant gains in its portfolio of companies going through IPOs, uplists, and spinoffs. Berkshire Hathaway, best known for its CEO Warren Buffet, one of the world’s wealthiest men and the “Oracle of Omaha”, owns big stakes in businesses in insurance, distribution, manufacturing, retailing, rail transportation, energy generation, and more. Insurance generates the most revenue for the company, but manufacturing generates the most earnings before taxes. Berkshire Hathaway’s stock is the most expensive stock on Nasdaq. On February 24, the stock was priced at $456,460 and currently has a market capitalization of about $670 billion. The company’s stock is so expensive that a single share is worth more than a house in many parts of the U.S. A Fast Rising Alternative? If you are an avid follower of Berkshire Hathaway’s business model and intrigued by how many businesses it has fostered, the name DSS, Inc. (NYSE American: DSS) could warrant attention. Unlike Warren Buffet’s company, which owns pure-play companies like Geico, DSS is not an investment firm but rather an incubator–building and spinning off companies with the goal of giving retail investors pure-play opportunities for additional stock. For some context, a spinoff occurs when a company splits off a portion of its business into a separate company and distributes shares of the new entity tax-free to the parent company’s shareholders. Some prominent companies that have pursued spinoffs include General Electric Company (NYSE: GE), Johnson & Johnson (NYSE: JNJ), and 3M Co. (NYSE: MMM). In joining these big players, DSS has evolved into a multi-industry business growing through acquisitions. The company has a diversified portfolio including biotech, a REIT focusing on healthcare facilities, a bank, and an alternative trading platform for token exchange, amongst other targeted businesses. The company’s Net Asset Value as of September 30 last year was $182.6 million, while Net Asset Value (NAV) per share was $1.31. Revenues were up by 172% year-on-year, total assets were $264 million, and asset growth was over 200%. DSS reports that its diversified, sustainable businesses driving strong cash flow and profitability are mainly: Premier Packaging Corporation — Innovative product and consumer packaging solutions. Impact Biomedical — Developing and acquiring companies and assets in biotech/healthcare. Decentralized Sharing Systems — Peer-to-peer decentralized distribution marketplace and direct marketing model DSS PureAir — Advanced technology that provides innovative, high-quality air and surface purification and filtration American Pacific Bancorp — Provides a complete range of banking and lending services DSS Securities — Investing and acquiring in fund management and market-making firm. Currently, with $1.7 billion assets under management. American Medical REIT — Medical REIT targets hospitals and acute care facilities in secondary and tertiary markets. Digital Securities Exchange — Developing and acquiring assets in securities trading and management, including digital asset exchanges and utility token exchanges. Spinoffs With The Goal Of Giving Investors Pure-Play Opportunities A Zacks Small-Cap Research report released in September 2022 revealed that DSS plans three (3) spinoffs in the next nine months: Impact Biomedical, American Pacific Bancorp, and American Medical REIT, with the first one, Impact Biomedical, potentially worth up to $160 million. The imminent spinoff of Impact Biomedical (its red herring has been filed) is in the comments phase with the U.S. Securities and Exchange Commission (SEC) with the eventual spinoff expected in the next quarter. Impact Biomedical is expected to file an amended S-1 and have a record date set in Q2 and could IPO within the next two quarters. The company’s valuation is expected to be determined by the bankers and the markets. DSS believes a spinoff of American Pacific Bancorp could happen quickly as it is a far less complicated entity — the spinoff could be executed by as early as the third quarter of 2023. “We expect it would be valued at the typical four to five times loans outstanding for commercial lenders, which currently stand at $40 million, thus valuing it at $160 million to $200 million. We believe it is earning approximately 10% on average on its loans. DSS’s current enterprise value is now $65 million,” the company said. AMRE REIT, on the other hand, has an 8% cap rate and is expected to reach $200 million to $250 million in assets before IPO’ing, which DSS anticipates could happen in Q3 of 2023. Again, this IPO process will provide DSS shareholders with a “no-cost” investment in a separately traded company. DSS says it plans to retain at least 50% of each entity in all three cases — the same will apply for future spinoffs beyond the initial three— but the Company assures shareholders would get a certain percentage. New shares will be issued to raise capital to support the growth of each newly public company. DSS appears to be a company that offers investors the opportunity to acquire a portfolio of curated pure-play companies in the form of stock dividends. In simple terms, when one of DSS’s companies goes public, if you own DSS stock, you’ll get their stock automatically, too — and benefit from individual increases in shareholder value with each spinoff. As DSS executes its business plan, more investors will most likely learn of these periodic spinoffs to participate in these ongoing stock dividends. This article was originally published on Benzinga here. DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details Rick Lutz- TraDigital IR rick@tradigitalir.com Company Website https://www.dssworld.com/

March 07, 2023 09:25 AM Eastern Standard Time

The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury

Unicycive Therapeutics, Inc.

By Julian Richard, Benzinga Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver quality of life due to kidney failure. Its candidate UNI-494 is currently in development for treating acute kidney injury (AKI). Acute kidney injury (AKI) is a serious, life-threatening condition caused by an acute loss of kidney function. There are several causes of AKI, including heart failure and liver disease, blockage to the kidney and reduced blood flow, and drugs or toxic substances. Recent research has highlighted the role that mitochondrial dysfunction plays in AKI pathogenesis. Mitochondria are organelles (specialized structures within cells that perform specific functions) that produce energy for cell functions and regulate many other biological processes, such as cell death. When mitochondria become dysfunctional due to illness or trauma, it can lead to various diseases, including AKI. Treatment for AKI currently focuses on supportive care measures such as administering fluids and electrolytes to stabilize the patient’s blood pressure and dialysis treatment to remove waste from the body. While these treatments are effective in treating the symptoms of AKI, they fail to address the underlying cause of this medical condition and thus do not affect the progression of the disease. Symptoms of AKI include decreased frequency of urination and swelling in the legs and may lead to chronic kidney disease if not treated. Unfortunately, treatment options for mitochondrial dysfunction are limited. While several promising treatments can restore mitochondrial function, such as using antioxidants and other compounds to reduce oxidative stress, these treatments have yet to be successfully implemented on a large scale. This unmet medical need has left many patients with few treatment options. UNI-494 is a promising compound seeking to address this unmet clinical need. It is a patented pro-drug (a biologically inactive compound that can be metabolized in the body to produce an active drug) of nicorandil, which has been shown in preclinical models to improve mitochondrial function. Data for UNI-494 from three pre-clinical studies will be presented at the National Kidney Foundation’s (NFK) upcoming Spring Clinical Meetings in April 2023. “We are delighted to be presenting this bolus of data in support of UNI-494 as a potential treatment advance for acute kidney injury” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive Therapeutics. Visit https://unicycive.com for more information on the company and its product candidates. This article was originally published on Benzinga here. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

March 07, 2023 09:00 AM Eastern Standard Time

1 ... 146 147 148 149 150 ... 302